The efficacy of zuranolone in postpartum depression and major depressive disorder: a review & number needed to treat (NNT) analysis

被引：3

作者：

Cha, Danielle S. ^{[1
,2
,3
,4
,5
]}

Kleine, Nicholas ^{[4
,6
]}

Teopiz, Kayla M. ^{[4
,6
]}

Di Vincenzo, Joshua D. ^{[3
,4
]}

Ho, Roger ^{[7
,8
]}

Galibert, Stephanie L. ^{[9
]}

Samra, Amrita ^{[5
]}

Zilm, Samuel P. M. ^{[5
]}

Cha, Rebekah H. ^{[10
]}

d'Andrea, Giacomo ^{[8
]}

Gill, Hartej ^{[3
,11
]}

Ceban, Felicia ^{[3
,4
,10
]}

Meshkat, Shakila ^{[3
]}

Wong, Sabrina ^{[3
,4
]}

Le, Gia Han ^{[3
,11
]}

Kwan, Angela T. H. ^{[3
,11
]}

Rosenblat, Joshua D. ^{[3
,4
,12
]}

Rhee, Taeho Greg ^{[13
,14
]}

Mansur, Rodrigo B. ^{[3
,4
]}

Mcintyre, Roger S. ^{[15
,16
,17
,18
,19
,20
,21
,22
,23
]}

机构：

[1] Royal Brisbane & Womens Hosp, Mental Hlth Serv, Brisbane, Qld, Australia

[2] Univ Queensland, Sch Clin Med, Royal Brisbane Clin Unit, Brisbane, Qld, Australia

[3] Brain & Cognit Fdn, Toronto, ON, Canada

[4] Univ Hlth Network, Toronto Western Hosp, Mood Disorders Psychopharmacol Dept, Toronto, ON, Canada

[5] Royal Brisbane & Womens Hosp, Metro North Hosp & Hlth Serv, Brisbane, Qld, Australia

[6] Univ Toronto, Dept Pharmacol, Toronto, ON, Canada

[7] Natl Univ Singapore, Inst Hlth Innovat & Technol iHealthtech, Singapore, Singapore

[8] Univ G dAnnunzio, Dept Neurosci Imaging & Clin Sci, Chieti, Italy

[9] Logan Hosp, Dept Obstet & Gynaecol, Logan, Qld, Australia

[10] McMaster Univ, Michael G DeGroote Sch Med, Hamilton, ON, Canada

[11] Univ Toronto, Inst Med Sci, Toronto, ON, Canada

[12] Univ Toronto, Dept Psychiat, Toronto, ON, Canada

[13] Yale Sch Med, Dept Psychiat, New Haven, CT USA

[14] Univ Connecticut, Sch Med, Dept Publ Hlth Sci, Farmington, CT USA

[15] Univ Toronto, Dept Psychiat & Pharmacol, Toronto, ON, Canada

[16] Brain & Cognit Discovery Fdn BCDF, Toronto, ON, Canada

[17] Depress & Bipolar Support Alliance DBSA Board Dire, Board Chair, Chicago, IL USA

[18] Guangzhou Med Univ, Guangzhou, Peoples R China

[19] Korea Univ, Coll Med, Seoul, South Korea

[20] Univ Philippines, Coll Med, Manila, Philippines

[21] SUNY Upstate Med Univ, State Univ New York, Syracuse, NY USA

[22] Univ Calif Riverside, Sch Med, Dept Psychiat & Neurosci, Riverside, CA USA

[23] Univ Toronto, 77 Bloor St West,6th Floor Suite 617, Toronto, ON M5S 1M2, Canada

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2024年 / 25卷 / 01期

基金：

加拿大健康研究院; 中国国家自然科学基金;

关键词：

Zuranolone; SAGE217; depression; postpartum/postpartum depression; rapid-acting; neuroactive steroid; GABA(A); positive allosteric modulator; COGNITIVE FUNCTION; ALLOSTERIC MODULATORS; MENTAL-DISORDERS; CLINICAL-TRIAL; IMPACT; HARM; ALPHAXALONE; OUTPATIENTS; IMPAIRMENT; LIKELIHOOD;

D O I：

10.1080/14656566.2023.2298340

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Introduction: Major depressive disorder (MDD) is a common and debilitating mental illness. Postpartum depression (PPD) impacts women globally and is one of the most common complications of childbirth that is underdiagnosed and undertreated, adversely impacting the mental health of women, children, and partners. Available antidepressant medications require weeks to months before showing effect. In this setting, zuranolone, an oral neuroactive steroid and a positive allosteric modulator of GABA(A) receptors, is an attractive alternative as a rapid-acting antidepressant treatment.Areas covered: This article reviews zuranolone (SAGE217), focusing on available clinical studies in individuals with PPD and MDD. This paper adds to the extant literature by presenting the efficacy data as Number Needed to Treat (NNT) to facilitate indirect comparisons with other antidepressants.Expert opinion: Zuranolone is a novel rapid-acting (i.e. two week course) oral antidepressant for the treatment of adults with PPD with ongoing clinical trials evaluating its efficacy in adults with MDD. Zuranolone is well tolerated with no significant safety concerns in any clinical trials completed to date. Zuranolone will be scheduled by the Drug Enforcement Agency (DEA).

引用

页码：5 / 14

页数：10

共 50 条

[1] The efficacy of zuranolone versus placebo in postpartum depression and major depressive disorder: a systematic review and meta-analysis
Winslow, Mackenzie
White, Emily
Rose, Suzanne J.
Salzer, Elijah
Nemec, Eric C.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2024, 46 (03) : 590 - 601
[2] Number Needed to Treat and Number Needed to Harm analysis of the zuranolone phase 2 clinical trial results in major depressive disorder
Arnaud, Alix
Suthoff, Ellison
Stenson, Katie
Werneburg, Brian
Hodgkins, Paul
Bonthapally, Vijayveer
Jonas, Jeffrey
Meyer, Kellie
O'Day, Ken
JOURNAL OF AFFECTIVE DISORDERS, 2021, 285 : 112 - 119
[3] Comment on "The efficacy of zuranolone versus placebo in postpartum depression and major depressive disorder: a systematic review and meta-analysis"
Kotake, Kazumasa
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2024, 46 (04) : 998 - 998
[4] Authors' response to comments on "The efficacy of zuranolone versus placebo in postpartum depression and major depressive disorder: a systematic review and meta-analysis"
Nemec II, Eric C.
Rose, Suzanne J.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2024, 46 (04) : 999 - 999
[5] THE NUMBER NEEDED TO TREAT (NNT) - AN ALTERNATIVE MEASURE OF EFFICACY
LAUPACIS, A
SACKETT, DL
CLINICAL AND INVESTIGATIVE MEDICINE-MEDECINE CLINIQUE ET EXPERIMENTALE, 1986, 9 (03): : A47 - A47
[6] Evaluating the safety and efficacy of zuranolone in the management of major depressive disorder and postpartum depression, with or without concurrent insomnia: a rigorous systematic review and meta-analysis
Raja, Adarsh
Ahmed, Saboor
Siddiqui, Muhammad Basit Ali
Mir, Syeda Lamiya
Kumar, Rakesh
Ahmed, Muhammad
Raja, Sandesh
Bin Amin, Shafin
Rahman, Hafsah Alim Ur
Deepak, Fnu
Asghar, Muhammad Sohaib
FRONTIERS IN PSYCHIATRY, 2024, 15
[7] Efficacy and safety of zuranolone in the treatment of major depressive disorder: a meta-analysis
Wang, Shuyu
Zhang, Wenxing
Liu, Zhang
Zhang, Tian
Wang, Yi
Li, Weihong
FRONTIERS IN NEUROSCIENCE, 2024, 17
[8] Zuranolone GABAA receptor positive allosteric modulator Treatment of major depressive disorder Treatment of postpartum depression
Mehta, R.
Bhandari, R.
Kuhad, A.
DRUGS OF THE FUTURE, 2019, 44 (06) : 443 - 451
[9] Treatment benefits of duloxetine in major depressive disorder as assessed by number needed to treat
Cookson, John
Gilaberte, Inmaculada
Desaiah, Durisala
Kajdasz, Daniel K.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2006, 21 (05) : 267 - 273
[10] Adjunctive Aripiprazole, Olanzapine, or Quetiapine for Major Depressive Disorder: An Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed
Citrome, Leslie
POSTGRADUATE MEDICINE, 2010, 122 (04) : 39 - 48

← 1 2 3 4 5 →